Myriad Genetics Inc (NAS:MYGN)
$ 25.29 0.7 (2.84%) Market Cap: 2.29 Bil Enterprise Value: 2.33 Bil PE Ratio: 0 PB Ratio: 3.01 GF Score: 75/100

Myriad Genetics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 12:50PM GMT
Release Date Price: $29.3 (+0.24%)
Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good morning, everyone, and welcome to the third and final day of the Goldman Sachs Healthcare Conference. I'm Matt Sykes, the Senior Life Sciences Tools & Diagnostics analyst here at Goldman. And we have the pleasure of welcoming Myriad Genetics' management team here. We have Paul Diaz, the President and Chief Executive Officer; and Bryan Riggsbee, the Chief Financial Officer.

Paul, Bryan, thanks so much for being with us today.

Paul J. Diaz
Myriad Genetics, Inc. - CEO, President & Director

Thank you, Matt.

R. Bryan Riggsbee
Myriad Genetics, Inc. - Executive VP, CFO & Treasurer

Thanks for having us.

Questions & Answers

Matthew Carlisle Sykes
Goldman Sachs Group, Inc., Research Division - Research Analyst

Great. Maybe, Paul, I'll turn it over to you first and kind of let you set the stage and just go over a couple of the key highlights for investors

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot